« Back
Home /
CJ-13,610

CJ-13,610

Item no.	HY-106200-5mg
Manufacturer	MedChem Express
CASRN	179420-17-8
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.01
Citations	[1]Fischer L, et al. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol. 2004;142(5):861-868.
Smiles	NC(C1(C2=CC(SC3=CC=C(N4C(C)=NC=C4)C=C3)=CC=C2)CCOCC1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Lipoxygenase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	393.50
Product Description	CJ-13, 610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM[1]. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO: 10 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-106200-5mg-safety-datasheet.pdf